A hitchhiker's guide through the COVID-19 galaxy
- PMID: 34563684
- PMCID: PMC8461017
- DOI: 10.1016/j.clim.2021.108849
A hitchhiker's guide through the COVID-19 galaxy
Abstract
Numerous reviews have summarized the epidemiology, pathophysiology and the various therapeutic aspects of Coronavirus disease 2019 (COVID-19), but a practical guide on "how to treat whom with what and when" based on an understanding of the immunological background of the disease stages remains missing. This review attempts to combine the current knowledge about the immunopathology of COVID-19 with published evidence of available and emerging treatment options. We recognize that the information about COVID-19 and its treatment is rapidly changing, but hope that this guide offers those on the frontline of this pandemic an understanding of the host response in COVID-19 patients and supports their ongoing efforts to select the best treatments tailored to their patient's clinical status.
Copyright © 2021 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4174-4184. doi: 10.26355/eurrev_202106_26061. Eur Rev Med Pharmacol Sci. 2021. PMID: 34156699 Review.
-
Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.Virus Res. 2021 Aug;301:198464. doi: 10.1016/j.virusres.2021.198464. Epub 2021 May 29. Virus Res. 2021. PMID: 34058265 Free PMC article.
-
Pathogenesis guided therapeutic management of COVID-19: an immunological perspective.Int Rev Immunol. 2021;40(1-2):54-71. doi: 10.1080/08830185.2020.1840566. Epub 2020 Oct 28. Int Rev Immunol. 2021. PMID: 33111578 Review.
-
COVID-19: Between Past and Present.Viral Immunol. 2021 Apr;34(3):145-157. doi: 10.1089/vim.2020.0102. Epub 2020 Oct 5. Viral Immunol. 2021. PMID: 33017280 Review.
-
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.Biochimie. 2020 Dec;179:85-100. doi: 10.1016/j.biochi.2020.09.018. Epub 2020 Sep 22. Biochimie. 2020. PMID: 32971147 Free PMC article. Review.
Cited by
-
Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies.PLoS One. 2023 Aug 11;18(8):e0288920. doi: 10.1371/journal.pone.0288920. eCollection 2023. PLoS One. 2023. PMID: 37566593 Free PMC article.
-
Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19.Medicina (Kaunas). 2022 Sep 1;58(9):1194. doi: 10.3390/medicina58091194. Medicina (Kaunas). 2022. PMID: 36143871 Free PMC article.
-
Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment.Front Pharmacol. 2022 Jun 2;13:842836. doi: 10.3389/fphar.2022.842836. eCollection 2022. Front Pharmacol. 2022. PMID: 35721224 Free PMC article.
References
-
- World Health Organization WHO Coronavirus (COVID-19) Dashboard 2021. https://covid19.who.int Available from:
-
- European Centers for Disease Prevention and Control Data on SARS-CoV-2 Variants in the EU/EEA 2021. https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covi... updated 09. Sept 2021. Available from:
-
- Centers for Disease Prevention and Control COVID Data Tracker. 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions Available from:
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical